» Articles » PMID: 8264238

Insulin-like Growth Factor-1 and Its Receptor Mediate the Autocrine Proliferation of Human Ovarian Carcinoma Cell Lines

Overview
Journal Lab Invest
Specialty Pathology
Date 1993 Dec 1
PMID 8264238
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: IGF-1 regulates the growth of diverse mammalian cell types including several human carcinoma cell lines. The IGF-1 receptor is a glycosylated heterodimer which, upon binding with IGF-1, undergoes tyrosine autophosphorylation. The autophosphorylation of the beta-receptor subunit is a strict requirement for its mitogenic properties.

Experimental Design: In this study, we have assessed the role of the IGF-1 receptor in the proliferation of ovarian carcinoma cell lines in culture. Effects of anti-sense and sense oligodeoxynucleotides to IGF-1 receptor RNA were tested.

Results: The human ovarian carcinoma cell lines OVCAR-3 and CaOV-3 both grew autonomously in serum-free medium, and their growth was further stimulated by the addition of IGF-1. Incubation of cells with anti-sense oligodeoxynucleotides corresponding to the IGF-1 receptor RNA markedly inhibited cell proliferation both in serum-free medium and in the presence of IGF-1. The inhibition of cell growth by the oligodeoxynucleotides corresponded to a reduction in the amount of detectable phosphorylated IGF-1 receptor.

Conclusions: The findings indicate that IGF-1 and its specific receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines.

Citing Articles

IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer.

Somri-Gannam L, Meisel-Sharon S, Hantisteanu S, Bar-Noy T, Sigal E, Groisman G Front Oncol. 2024; 14:1410447.

PMID: 39450263 PMC: 11499063. DOI: 10.3389/fonc.2024.1410447.


Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.

Sun Y, Yin Z, Li S, Wu L, Zhang Y, Zhao Y Br J Cancer. 2024; 131(10):1683-1693.

PMID: 39369055 PMC: 11554678. DOI: 10.1038/s41416-024-02863-9.


Prospective Analysis of Circulating Biomarkers and Ovarian Cancer Risk in the UK Biobank.

Sasamoto N, Hathaway C, Townsend M, Terry K, Trabert B, Tworoger S Cancer Epidemiol Biomarkers Prev. 2024; 33(10):1347-1355.

PMID: 39007864 PMC: 11446659. DOI: 10.1158/1055-9965.EPI-24-0319.


Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins.

Almeida-Nunes D, Silvestre R, Dinis-Oliveira R, Ricardo S Int J Mol Sci. 2024; 25(1).

PMID: 38203494 PMC: 10779012. DOI: 10.3390/ijms25010323.


Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises.

Skorda A, Bay M, Hautaniemi S, Lahtinen A, Kallunki T Cancers (Basel). 2022; 14(24).

PMID: 36551745 PMC: 9777107. DOI: 10.3390/cancers14246257.